Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
+0.55 (1.72%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.95 - 32.60
52 week 20.24 - 33.33
Open 31.99
Vol / Avg. 956,392.00/1.66M
Mkt cap 9.10B
P/E 178.59
Div/yield     -
EPS 0.18
Shares 279.95M
Beta 1.28
Inst. own 98%
Apr 28, 2015
Q2 2015 Hologic Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
Hologic Inc at Barclays Healthcare Conference - Webcast
Mar 4, 2015
Hologic Inc at Cowen Health Care Conference - Webcast
Mar 3, 2015
Hologic Inc Annual Shareholders Meeting
Feb 11, 2015
Hologic Inc at Leerink Global Healthcare Conference - Webcast
Jan 28, 2015
Q1 2015 Hologic Inc Earnings Call - Webcast
Jan 28, 2015
Q1 2015 Hologic Inc Earnings Release
Jan 13, 2015
Hologic Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 4.47% 0.68%
Operating margin 14.83% 10.76%
EBITD margin - 34.41%
Return on average assets 1.42% 0.20%
Return on average equity 5.62% 0.86%
Employees 5,351 -
CDP Score - -


35 Crosby Dr
BEDFORD, MA 01730-1450
United States - Map
+1-781-9997300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Company�s business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company�s diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Company�s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Officers and directors

David R. LaVance Jr. Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Stephen P. MacMillan President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Robert W. McMahon Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Eric Compton Chief Operating Officer
Bio & Compensation  - Reuters
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Claus Egstrand Senior Vice President, General Manager - International
Bio & Compensation  - Reuters
Roger D. Mills Group Senior Vice President, General Manager - Service and Operations
Age: 58
Bio & Compensation  - Reuters
Allison Bebo Senior Vice President - Human Resources
Bio & Compensation  - Reuters
David P. Harding Senior Vice President - Corporate Strategy
Age: 48
Bio & Compensation  - Reuters
John Griffin General Counsel
Bio & Compensation  - Reuters